- We're hiring great biologists! At least we will be if we get your resume (or the resume of one of your extraordinary colleagues). We're building the team that creates the industry's leading cellular trafficking assays, and we're starting with biologists with experience in cell-culture, molecular biology and assay development for high throughput screening. Please check out our careers page, and forward along to qualified candidates. We'll be posting additional positions in the coming weeks. Exciting times!?
- We've just released a new PgP(G268V) mutant trafficking assay.
This assay has been used as selectivity assay when developing CFTR trafficking compounds. For example, Vertex's VX-809 clinical candidate increases CFTR trafficking, but does not also increase PgP trafficking. However, and earlier, less selective compound VRT-325 increases surface expression of CFTR and PgP.
The assay is available as a service, and we can also provide you with cells to run the assay in your own lab. Just let us know...?
- hERG Trafficking Assay in Development
We're getting ready to release a new trafficking assay for hERG, for cardiotox testing, and as an important selectivity screen for compounds aimed at correcting trafficking defects (especially for those studying correctors of CFTR mis-folding). Just like CFTR, we'll have wild-type and mutant hERG assays available.
The assays will initially be available as a service for profiling compounds, and as we get assay protocols fully optimized, we'll make cell-lines and assay kits available.
See http://www.sharpedgelabs.com/on-the-bench/herg-trafficking/ for details.?
- Cystic Fibrosis Assays Now Available
We've just moved our CFTR assay from "on the bench" to "off the shelf!"
The assay tracks cell-surface expression of both wild-type and ?F508 CFTR. By using cell-excluded, and cell-permeant dyes we can directly measure both surface and total protein. This allows us to distinguish different CFTR rescue mechanisms (for example, compounds that shift the Surface/ER equilibrium, versus compounds that increase total protein, and thus surface protein, without specifically increasing the fraction at the cell-surface).
We've also included an Application Note, where we test several known CFTR correctors, alone and in synergistic combinations.
The assay is available as a service, or as reagents for more advanced users (we can train in the use of the assay). The assay is running using high-speed flow cytometry.
We're excited to be able to bring this important new assay on-line for our customers. Have a look and contact us if you'd like to test some compounds in the assay.?
- For Immediate Release
Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors.
Sharp Edge Labs and SpectraGenetics, two Pittsburgh-based biotechnology companies, have entered into an Assay Development Agreement that will allow the companies to offer their industry leading assays for studying the detailed function of an important class of pharmaceutical targets, the G-Protein Coupled Receptors, or GPCRs. GPCRs are the most common target of today?s blockbuster drugs, including drugs for diseases ranging from hypertension and allergy to migraines, pain and cancer. ?While GPCRs are among the most-studied drug targets, we are just now learning important new aspects of how they work. These assays provide unprecedented detail in understanding these new aspects of activity for the industry's most valuable drug targets? said Dr. Scott Sneddon, Ph.D., J.D., President and CEO of Sharp Edge Labs.
?Working together, we can now offer a comprehensive set of tools for pharmaceutical and academic researchers including reagents and read-to-run assay kits, as well as assay services for profiling and screening compounds? added Dr. Reid Asbury, Ph.D., CEO of SpectraGenetics. ?Several large-pharma customers are already using the technology to study so-called ?ligand bias? or ?functional selectivity? of GPCRs. By combining SpectraGenetics? catalog of over 150 GPCRs with Sharp Edge Labs? assay development expertise, we believe we can help researchers address any question in this important new field of drug research? he added.
SpectraGenetics provides research reagents to the pharma/biotech industry and academic labs. SpectraGenetics has a large catalog of tagged genes, including a large selection of tagged GPCRs. Sharp Edge Labs is the exclusive licensee of the Fluorogen Activating Peptide technology from CMU and provides assay products and services for pharma/biotech researchers in the areas of Receptors, Ion Channels and Transporters. The company?s web-sites are www.spectragenetics.com and www.sharpedgelabs.com. Detailed images of the technology in use suitable for print or web publication can be found at www.sharpedgelabs.com/media-images ?